Andrei Floroiu Vaxart CEO Rating
Where This Score Ranks Vaxart's CEO Rating
- BOTTOM10%
In the Bottom 10% of 2054 Similar Sized Companies on Comparably
- BOTTOM10%
In the Bottom 10% of 932 Nearby Companies in San Francisco
- ?
Not enough ratings to compare against competitors.
Vaxart CEO Andrei Floroiu Bio
Mr. Floroiu has been a member of our board of directors since April 2020 and the CEO since June 15, 2020. Mr. Floroiu was most recently with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine. Prior to Agenus, Mr. Floroiu was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. Mr. Floroiu also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, a leading management consultancy. Mr. Floroiu holds an MBA from the Wharton School, an MSc from the University of Maryland, and an Engineering degree from the Politechnica University of Bucharest.
Vaxart CEO Andrei Floroiu At a Glance
The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Vaxart.
Overall, the CEO score has remained stable over the last 90 days.
Vaxart CEO Andrei Floroiu Rating Trendline
- Vaxart55
- Other Companies in San Francisco
- Similar Size on Comparably
Vaxart's CEO Rating Rank Against Similar Sized Companies on Comparably
Vaxart ranks in the Bottom 10% of other companies on Comparably with 11-50 Employees for CEO Rating Score.
Vaxart's CEO Rating Rank Against Other Companies Nearby
Vaxart ranks in the Bottom 10% of other companies in San Francisco for CEO Rating Score.
